Form 8-K - Current report:
SEC Accession No. 0001599298-24-000036
Filing Date
2024-03-05
Accepted
2024-03-05 16:05:09
Documents
18
Period of Report
2024-03-05
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K smmt-20240305.htm   iXBRL 8-K 28845
2 EX-99.1 a2024_prx0305xbarclayste.htm EX-99.1 8352
7 a2024_prx0305xbarclayste001.jpg GRAPHIC 257367
8 a2024_prx0305xbarclayste002.jpg GRAPHIC 253140
  Complete submission text file 0001599298-24-000036.txt   900555

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20240305.xsd EX-101.SCH 2161
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT smmt-20240305_def.xml EX-101.DEF 14787
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20240305_lab.xml EX-101.LAB 28738
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20240305_pre.xml EX-101.PRE 15429
19 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20240305_htm.xml XML 2735
Mailing Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025
Business Address 2882 SAND HILL ROAD SUITE 106 MENLO PARK CA 94025 650-460-8308
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36866 | Film No.: 24720236
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)